Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Eli Lilly and Co.
-
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
UPDATE: Lilly reports robust Q4, full-year earnings
Lilly’s fourth-quarter earnings, released before the market opened Thursday, surpassed analysts’ expectations by millions.
Read More -
Roche gets FDA clearance for test of emerging cardiovascular disease risk factor
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Read More
Articles
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
Lilly cuts undisclosed number of jobs, ‘nothing large scale’
The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new manufacturing facilities at four yet-to-be-named U.S. locations.
LEAP spending nears $1B with projected budget shielded, investigation finds
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Roughly 16 million people—that’s 6 percent of American adults—are taking GLP-1 weight-loss drugs, and that number is growing rapidly. Their collective purchasing power has the potential to profoundly reshape the economy.
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District
IMAGE GALLERY: The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
New life sciences consortium aims to give Indiana researchers better access to health data
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
Sweeping review looks at effect of weight-loss drugs on 175 conditions
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Lilly sees new weight-loss pill approval in early 2026, CEO says
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
Medicaid coverage of weight-loss drugs could cost state up to $70 million a year
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
State’s big, bold LEAP District play draws some reflection
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic leaders say the project is a huge success, but some political leaders are cautious.
2024 Newsmaker: Lilly CEO David Ricks
Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $972 and announcements about big new investments in Lebanon and Ireland.
2024 Year in Review: Lilly’s total investment at LEAP climbs to $13.5B
Lilly said the expansion is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
LEAP district developments among year’s top tech stories
The ongoing progress to develop the planned LEAP Innovation and Research District, a 9,000-acre tech park in Boone County, was among the top local tech stories of 2024.